Patients (n=22) |
Controls (n=22) |
|||
---|---|---|---|---|
Biopsy |
Pre-operative chemotherapy |
Post-operative chemotherapy |
||
BALP (U/L) | 136.9 (85.7-240.6) | 53.8 (40.4-84.8)* | 63.8 (43.2-82.4)** | 94.1 (59.4-120.4)** |
ECD/HER-2 (ng/ml) | 4.95 (3.53-12.3) | 3.86 (2.79-10.08)* | 3.84 (3.06-20.66)* | 4.06 (3.29-5.20)* |
Patients with localized disease (n=13) |
Patients with metastatic disease (n=9) |
|||||
---|---|---|---|---|---|---|
Biopsy |
Pre-operative chemotherapy |
Post-operative chemotherapy |
Biopsy |
Pre-operative chemotherapy |
Post-operative chemotherapy |
|
BALP (U/L) | 89.1(75.4-138.8) | 43.0** (31.9-58.0) | 50.5** (36.8-80.5) | 257.0** (216.5-325.7) | 101.6* (49.7-142.6) | |
ECD/HER-2 (ng/ml) | 4.58 (3.40-14.20) | 3.86 (2.86-12.9) | 7.98* (3.31-20.66) | 5.11(3.68-6.90) | 3.80 (2.44-5.76) | 3.62 (2.59-6.88) |
Patients with remission (n=16) |
Patients with progression (n=6) |
|
---|---|---|
BALP (U/L) | 43.6 (38.4-74.6) | 147.0 (126.5-263.3)* |
ECD/HER-2 (ng/ml) | 3.56 (2.61-37.62) | 6.41 (4.51-10.59) |